Characterisation of tumor‐infiltrating gamma‐delta T cells in human colorectal cancer with MHC‐I loss
Clinical & Translational Immunology · 2026-05 · 15 (5)
DOI: 10.1002/cti2.70097 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Translational Immunology, online erschienen am 12.05.2026. Verfasst von Tianming A Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Olivia Newton-John Cancer Research Institute Heidelberg VIC Australia. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Austin Medical Research Foundation, Victorian Cancer Agency, Tour de Cure.
Abstract (Originalsprache)
Objectives
Gamma‐delta (γδ) T cells have been associated with favorable prognoses across several malignancies, underscoring their potential as targets for novel immunotherapies. These unconventional T lymphocytes exhibit an intrinsic tropism for the tumor microenvironment, largely driven by their capacity to recognize stress‐induced antigens characteristic of metabolically dysregulated tumors. Unlike the mechanism governing conventional cytotoxic CD8 + alpha‐beta (αβ) T cells, γδ T‐cell receptors can engage tumor cell moieties independent of major histocompatibility complex class‐I (MHC‐I) and human leukocyte class‐I molecules. Therefore, γδ T cells may have a pivotal role in the immune response to beta‐2 microglobulin‐mutated MHC‐I negative (MHC‐I − ) colorectal cancers (CRCs) with deficient mismatch repair.
Methods
To determine whether γδ T‐cell mobilisation extends to diverse aetiologies of MHC‐I loss, we used multispectral immunohistochemistry to stain 150 stage I‐IV primary CRC tissues, across eight tissue microarrays.
Results
Our investigation revealed MHC‐I loss in ~30% of CRC primary tumors across all disease stages, with a notable increase in stromal γδ T‐cell frequency and activation status among stage III cases. Importantly, these findings extend previous observations largely confined to mismatch repair–deficient CRC by demonstrating that stromal γδ T‐cell enrichment associated with MHC‐I loss also occurs in mismatch repair–proficient tumors, suggesting a broader role for γδ T cells in immune surveillance of MHC‐I–deficient CRC.
Conclusion
These data highlight the potential of γδ T cells in counteracting immune evasive MHC‐I − tumors, thereby offering a robust rationale for their strategic deployment in next‐generation immunotherapy regimens.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Olivia Newton-John Cancer Research Institute Heidelberg VIC Australia.
- School of Cancer Medicine La Trobe University Heidelberg VIC Australia.
- Department of Cancer Medicine, School of Translational Medicine Monash University Melbourne VIC Australia.
- Department of Pathology Austin Health Heidelberg VIC Australia.
- Department of Medicine University of Melbourne Parkville VIC Australia.
ORCID-Profile: Jessica Da Gama Duarte
Förderung
- Austin Medical Research Foundation
- Victorian Cancer Agency
- Tour de Cure
Zitieren
APA
Li, T. A., Quigley, L. T., Chan, K. F., Williams, D. S., Mielke, L. A., Behren, A., & Da Gama Duarte, J. (2026). Characterisation of tumor‐infiltrating gamma‐delta T cells in human colorectal cancer with MHC‐I loss. Clinical & Translational Immunology, 15(5). https://doi.org/10.1002/cti2.70097
Vancouver
Li TA, Quigley LT, Chan KF, Williams DS, Mielke LA, Behren A, et al. Characterisation of tumor‐infiltrating gamma‐delta T cells in human colorectal cancer with MHC‐I loss. Clinical & Translational Immunology. 2026;15(5). doi:10.1002/cti2.70097
BibTeX
@article{Li2026,
author = {Li, Tianming A and Quigley, Luke T and Chan, Kok Fei and Williams, David S and Mielke, Lisa A and Behren, Andreas and Da Gama Duarte, Jessica},
title = {Characterisation of tumor‐infiltrating gamma‐delta T cells in human colorectal cancer with MHC‐I loss},
journal = {Clinical & Translational Immunology},
year = {2026},
volume = {15},
number = {5},
doi = {10.1002/cti2.70097}
}
EUVIMED